Cargando…

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) accounts for about 20% to 30% of all BC subtypes and is characterized by invasive disease and poor prognosis. With the emergence of anti-HER2 target drugs, HER2-positive BC patient outcomes have changed dramatically. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xue, Wu, Dapeng, Yuan, Shengli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592330/
https://www.ncbi.nlm.nih.gov/pubmed/33034269
_version_ 1783601164587106304
author Yang, Xue
Wu, Dapeng
Yuan, Shengli
author_facet Yang, Xue
Wu, Dapeng
Yuan, Shengli
author_sort Yang, Xue
collection PubMed
description Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) accounts for about 20% to 30% of all BC subtypes and is characterized by invasive disease and poor prognosis. With the emergence of anti-HER2 target drugs, HER2-positive BC patient outcomes have changed dramatically. However, treatment failure is mostly due to drug resistance and the special treatment needs of different subgroups. Small molecule tyrosine kinase inhibitors can inhibit multiple targets of the human epidermal growth factor receptor family and activate PI3K/AKT, MAPK, PLC γ, ERK1/2, JAK/STAT, and other pathways affecting the expression of MDM2, mTOR, p27, and other transcription factors. This can help regulate the differentiation, apoptosis, migration, growth, and adhesion of normal cells and reverse drug resistance to a certain extent. These inhibitors can cross the blood-brain barrier and be administered orally. They have a good synergistic effect with effective drugs such as trastuzumab, pertuzumab, t-dm1, and cyclin-dependent kinase 4 and 6 inhibitors. These advantages have resulted in small-molecule tyrosine kinase inhibitors attracting attention. The new small-molecule tyrosine kinase inhibitor was investigated in multi-target anti-HER2 therapy, showed a good effect in preclinical and clinical trials, and to some extent, improved the prognosis of HER2-positive BC patients. Its use could lead to a de-escalation of treatment in some patients, possibly preventing unnecessary procedures along with the associated side effects and costs.
format Online
Article
Text
id pubmed-7592330
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75923302020-11-10 Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer Yang, Xue Wu, Dapeng Yuan, Shengli Technol Cancer Res Treat Review Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) accounts for about 20% to 30% of all BC subtypes and is characterized by invasive disease and poor prognosis. With the emergence of anti-HER2 target drugs, HER2-positive BC patient outcomes have changed dramatically. However, treatment failure is mostly due to drug resistance and the special treatment needs of different subgroups. Small molecule tyrosine kinase inhibitors can inhibit multiple targets of the human epidermal growth factor receptor family and activate PI3K/AKT, MAPK, PLC γ, ERK1/2, JAK/STAT, and other pathways affecting the expression of MDM2, mTOR, p27, and other transcription factors. This can help regulate the differentiation, apoptosis, migration, growth, and adhesion of normal cells and reverse drug resistance to a certain extent. These inhibitors can cross the blood-brain barrier and be administered orally. They have a good synergistic effect with effective drugs such as trastuzumab, pertuzumab, t-dm1, and cyclin-dependent kinase 4 and 6 inhibitors. These advantages have resulted in small-molecule tyrosine kinase inhibitors attracting attention. The new small-molecule tyrosine kinase inhibitor was investigated in multi-target anti-HER2 therapy, showed a good effect in preclinical and clinical trials, and to some extent, improved the prognosis of HER2-positive BC patients. Its use could lead to a de-escalation of treatment in some patients, possibly preventing unnecessary procedures along with the associated side effects and costs. SAGE Publications 2020-10-09 /pmc/articles/PMC7592330/ /pubmed/33034269 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Yang, Xue
Wu, Dapeng
Yuan, Shengli
Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
title Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
title_full Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
title_fullStr Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
title_full_unstemmed Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
title_short Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
title_sort tyrosine kinase inhibitors in the combination therapy of her2 positive breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592330/
https://www.ncbi.nlm.nih.gov/pubmed/33034269
work_keys_str_mv AT yangxue tyrosinekinaseinhibitorsinthecombinationtherapyofher2positivebreastcancer
AT wudapeng tyrosinekinaseinhibitorsinthecombinationtherapyofher2positivebreastcancer
AT yuanshengli tyrosinekinaseinhibitorsinthecombinationtherapyofher2positivebreastcancer